Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Mol Ther ; 26(3): 730-743, 2018 03 07.
Article in English | MEDLINE | ID: mdl-29433936

ABSTRACT

Analysis of microRNA (miR) expression in the central nervous system white matter of SJL mice infected with the BeAn strain of Theiler's murine encephalomyelitis virus (TMEV) revealed a significant reduction of miR-219, a critical regulator of myelin assembly and repair. Restoration of miR-219 expression by intranasal administration of a synthetic miR-219 mimic before disease onset ameliorates clinical disease, reduces neurogliosis, and partially recovers motor and sensorimotor function by negatively regulating proinflammatory cytokines and virus RNA replication. Moreover, RNA sequencing of host lesions showed that miR-219 significantly downregulated two genes essential for the biosynthetic cholesterol pathway, Cyp51 (lanosterol 14-α-demethylase) and Srebf1 (sterol regulatory element-binding protein-1), and reduced cholesterol biosynthesis in infected mice and rat CG-4 glial precursor cells in culture. The change in cholesterol biosynthesis had both anti-inflammatory and anti-viral effects. Because RNA viruses hijack endoplasmic reticulum double-layered membranes to provide a platform for RNA virus replication and are dependent on endogenous pools of cholesterol, miR-219 interference with cholesterol biosynthesis interfered virus RNA replication. These findings demonstrate that miR-219 inhibits TMEV-induced demyelinating disease through its anti-inflammatory and anti-viral properties.


Subject(s)
Cardiovirus Infections/complications , Cardiovirus Infections/virology , Demyelinating Diseases/etiology , Demyelinating Diseases/pathology , MicroRNAs/genetics , Theilovirus , Viral Load , Animals , Biomarkers , Cell Line , Cholesterol/metabolism , Cytokines/metabolism , Demyelinating Diseases/metabolism , Disease Models, Animal , Female , Fibrinogen/metabolism , Gene Expression Regulation , Inflammation Mediators/metabolism , Lipid Metabolism/genetics , Mice , Microglia/metabolism , RNA Interference , Rats
2.
J Neurosci ; 33(24): 10048-56, 2013 Jun 12.
Article in English | MEDLINE | ID: mdl-23761900

ABSTRACT

Loss of function of galactosylceramidase lysosomal activity causes demyelination and vulnerability of various neuronal populations in Krabbe disease. Psychosine, a lipid-raft-associated sphingolipid that accumulates in this disease, is thought to trigger these abnormalities. Myelin-free in vitro analyses showed that psychosine inhibited fast axonal transport through the activation of axonal PP1 and GSK3ß in the axon. Abnormal levels of activated GSK3ß and abnormally phosphorylated kinesin light chains were found in nerve samples from a mouse model of Krabbe disease. Administration of GSK3ß inhibitors significantly ameliorated transport defects in vitro and in vivo in peripheral axons of the mutant mouse. This study identifies psychosine as a pathogenic sphingolipid able to block fast axonal transport and is the first to provide a molecular mechanism underlying dying-back degeneration in this genetic leukodystrophy.


Subject(s)
Axonal Transport/drug effects , Glycogen Synthase Kinase 3/metabolism , Leukodystrophy, Globoid Cell/pathology , Molecular Motor Proteins/metabolism , Neurons/pathology , Psychosine/pharmacology , Analysis of Variance , Animals , Animals, Newborn , Cells, Cultured , Cerebral Cortex/pathology , Disease Models, Animal , Embryo, Mammalian , Enzyme Inhibitors/pharmacology , Gene Expression Regulation, Developmental/drug effects , Gene Expression Regulation, Developmental/genetics , Glycogen Synthase Kinase 3 beta , Leukodystrophy, Globoid Cell/drug therapy , Leukodystrophy, Globoid Cell/genetics , Membrane Microdomains/drug effects , Membrane Microdomains/enzymology , Mice , Mice, Inbred C57BL , Mice, Mutant Strains , Microscopy, Electron, Transmission , Mitochondria/drug effects , Mitochondria/physiology , Nerve Tissue Proteins/metabolism , Neurons/drug effects , Neurons/ultrastructure , Sciatic Nerve/pathology , Time Factors
3.
J Neurosci Res ; 88(14): 3161-70, 2010 Nov 01.
Article in English | MEDLINE | ID: mdl-20818775

ABSTRACT

Injection into the injured spinal cord of peptide amphiphile (PA) molecules that self-assemble and display the laminin epitope IKVAV at high density improved functional recovery after spinal cord injury (SCI) in two different species, rat and mouse, and in two different injury models, contusion and compression. The improvement required the IKVAV epitope and was not observed with the injection of an amphiphile displaying a nonbioactive sequence. To explore the mechanisms underlying these improvements, the number of serotonergic fibers in the lesioned spinal cord was compared in animals receiving the IKVAV-PA, a nonbioactive PA (PA control), or sham injection. Serotonergic fibers were distributed equally in all three groups rostral to the injury but showed a significantly higher density caudal to the injury site in the IKVAV PA-injected group. Furthermore, this difference was not present in the subacute phase following injury but appeared in the chronically injured cord. The IKVAV PA-injected groups also trended higher both in the total number neurons adjacent to the lesion and in the number of long propriospinal tract connections from the thoracic to the lumbar cord. IKVAV PA injection did not alter myelin thickness, total axon number caudal to the lesion, axon size distribution, or total axon area. Serotonin can promote stepping even in complete transection models, so the improved function produced by the IKVAV PA treatment may reflect the increased serotonergic innervation caudal to the lesion in addition to the previously demonstrated regeneration of motor and sensory axons through the lesion.


Subject(s)
Nerve Fibers/drug effects , Neuronal Plasticity/drug effects , Serotonin/physiology , Spinal Cord Injuries/drug therapy , Surface-Active Agents/pharmacology , Animals , Cell Count , Disease Models, Animal , Female , Laminin/administration & dosage , Laminin/physiology , Mice , Mice, 129 Strain , Nanofibers , Nerve Fibers/physiology , Nerve Regeneration/drug effects , Nerve Regeneration/physiology , Neuronal Plasticity/physiology , Peptide Fragments/administration & dosage , Peptides/administration & dosage , Rats , Rats, Long-Evans , Spinal Cord Injuries/metabolism
4.
J Neurosci ; 30(5): 1839-55, 2010 Feb 03.
Article in English | MEDLINE | ID: mdl-20130193

ABSTRACT

Astrogliosis following spinal cord injury (SCI) involves an early hypertrophic response that is beneficial and a subsequent formation of a dense scar. We investigated the role of bone morphogenetic protein (BMP) signaling in gliosis after SCI and find that BMPR1a and BMPR1b signaling exerts opposing effects on hypertrophy. Conditional ablation of BMPR1a from glial fibrillary acidic protein (GFAP)-expressing cells leads to defective astrocytic hypertrophy, increased infiltration by inflammatory cells, and reduced axon density. BMPR1b-null mice conversely develop "hyperactive" reactive astrocytes and consequently have smaller lesion volumes. The effects of ablation of either receptor are reversed in the double knock-out animals. These findings indicate that BMPR1a and BMPR1b exert directly opposing effects on the initial reactive astrocytic hypertrophy. Also, BMPR1b knock-out mice have an attenuated glial scar in the chronic stages following injury, suggesting that it has a greater role in glial scar progression. To elucidate the differing roles of the two receptors in astrocytes, we examined the effects of ablation of either receptor in serum-derived astrocytes in vitro. We find that the two receptors exert opposing effects on the posttranscriptional regulation of astrocytic microRNA-21. Further, overexpression of microRNA-21 in wild-type serum-derived astrocytes causes a dramatic reduction in cell size accompanied by reduction in GFAP levels. Hence, regulation of microRNA-21 by BMP signaling provides a novel mechanism for regulation of astrocytic size. Targeting specific BMPR subunits for therapeutic purposes may thus provide an approach for manipulating gliosis and enhancing functional outcomes after SCI.


Subject(s)
Bone Morphogenetic Protein Receptors, Type I/metabolism , Gliosis/physiopathology , Spinal Cord Injuries/physiopathology , Animals , Astrocytes/metabolism , Axons/ultrastructure , Cells, Cultured , Female , Gliosis/pathology , Hyperplasia/pathology , Hyperplasia/physiopathology , Mice , Mice, Knockout , Mice, Transgenic , MicroRNAs/metabolism , STAT3 Transcription Factor/metabolism , Smad Proteins/metabolism , Spinal Cord Injuries/pathology , Up-Regulation
SELECTION OF CITATIONS
SEARCH DETAIL
...